Lord, Abbett & Co
PACB icon

Lord, Abbett & Co’s Pacific Biosciences PACB Stock Holding History

Lord, Abbett & Co’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,442,956
Closed -$24M – 575
2023
Q4 		$24M Sell
2,442,956
-1,222,921
-33% -$10M 0.08% 304
2023
Q3 		$30.6M Sell
3,665,877
-17,989
-0.5% -$206K 0.11% 250
2023
Q2 		$49M Buy
3,683,866
+251,862
+7% +$3.06M 0.17% 181
2023
Q1 		$39.7M Sell
3,432,004
-780,131
-19% -$7.76M 0.14% 219
2022
Q4 		$34.5M Buy
+4,212,135
New +$36.3M 0.12% 243
2021
Q2 		– Sell
-1,019,453
Closed -$34M – 687
2021
Q1 		$34M Sell
1,019,453
-1,190,872
-54% -$41.7M 0.09% 333
2020
Q4 		$57.3M Sell
2,210,325
-522,875
-19% -$8.89M 0.15% 220
2020
Q3 		$27M Buy
+2,733,200
New +$15.7M 0.09% 321
2017
Q4 		– Sell
-814,484
Closed -$4.28M – 893
2017
Q3 		$4.28M Buy
814,484
+221,473
+37% +$952K 0.01% 787
2017
Q2 		$2.11M Sell
593,011
-294,233
-33% -$1.19M 0.01% 854
2017
Q1 		$4.59M Sell
887,244
-1,806,474
-67% -$8.84M 0.01% 761
2016
Q4 		$10.2M Sell
2,693,718
-3,700,646
-58% -$26.9M 0.03% 572
2016
Q3 		$57.3M Buy
6,394,364
+227,271
+4% +$1.9M 0.17% 185
2016
Q2 		$43.4M Buy
6,167,093
+2,510,152
+69% +$22.9M 0.14% 233
2016
Q1 		$31.1M Buy
3,656,941
+37,682
+1% +$371K 0.1% 309
2015
Q4 		$47.5M Buy
+3,619,259
New +$32.5M 0.14% 217
2015
Q3 		– Sell
-608,985
Closed -$3.51M – 946
2015
Q2 		$3.51M Buy
608,985
+137,832
+29% +$797K 0.01% 818
2015
Q1 		$2.75M Buy
+471,153
New +$3.25M 0.01% 822

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Lord, Abbett & Co's PACB Position: Q1 2024 in Review

Lord, Abbett & Co sold out of Pacific Biosciences (PACB) in Q1 2024, closing a stake of 2,442,956 shares — an estimated $24M sold.

Lord, Abbett & Co first reported a position in PACB in Q1 2015 and held it in 18 quarters. The position peaked at $57.3M in Q4 2020. 268 funds tracked by Wall St. Rank hold PACB as of Q1 2024.

  • Lord, Abbett & Co reported no remaining Pacific Biosciences position as of Q1 2024 after selling out during the quarter.
  • Lord, Abbett & Co sold 2,442,956 Pacific Biosciences shares in Q1 2024, an estimated $24M.
  • Lord, Abbett & Co first reported a position in Pacific Biosciences in Q1 2015 and held it in 18 quarters.
  • Lord, Abbett & Co's Pacific Biosciences position peaked at $57.3M in Q4 2020.
  • 268 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2024.

Based on Lord, Abbett & Co's 13F filing for Q1 2024, filed 9 May 2024.